A review of antibiotic therapy for pelvic inflammatory disease

Research output: Contribution to journalArticlepeer-review

Standard

A review of antibiotic therapy for pelvic inflammatory disease. / Duarte, Rui; Fuhrich, Daniele; Ross, Jonathan D C.

In: International Journal of Antimicrobial Agents, Vol. 46, No. 3, 09.2015, p. 272-277.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Duarte, Rui ; Fuhrich, Daniele ; Ross, Jonathan D C. / A review of antibiotic therapy for pelvic inflammatory disease. In: International Journal of Antimicrobial Agents. 2015 ; Vol. 46, No. 3. pp. 272-277.

Bibtex

@article{4eb4eab7e4554252a314f21d3289268e,
title = "A review of antibiotic therapy for pelvic inflammatory disease",
abstract = "Pelvic inflammatory disease (PID) is a gynaecological inflammatory disorder with a high incidence that can lead to sequelae such as infertility, ectopic pregnancy and chronic pelvic pain. The International Union against Sexually Transmitted Infections (IUSTI) and the US Centers for Disease Control and Prevention (CDC) have issued treatment recommendations for the management of PID. The purpose of this review is to summarise the available evidence for the use of IUSTI- and CDC-recommended antibiotic therapies for PID. The main differences between recommendations concern alternative regimens for inpatient treatment and the use of oral moxifloxacin as an alternative outpatient regimen in the IUSTI guidelines. There is evidence supporting the use of the recommended antibiotic regimens, although with some variation in reported cure rates. This variation can be explained, in part, by the different diagnostic and evaluation criteria used in different trials. Adverse events that require discontinuation of antibiotic therapy are rarely observed. The main limitation of the current available evidence is the short-term follow-up, which does not allow full evaluation of the risks of long-term sequelae.",
keywords = "Antibiotic therapy, CDC guidelines, IUSTI guidelines, Pelvic inflammatory disease",
author = "Rui Duarte and Daniele Fuhrich and Ross, {Jonathan D C}",
year = "2015",
month = sep,
doi = "10.1016/j.ijantimicag.2015.05.004",
language = "English",
volume = "46",
pages = "272--277",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - A review of antibiotic therapy for pelvic inflammatory disease

AU - Duarte, Rui

AU - Fuhrich, Daniele

AU - Ross, Jonathan D C

PY - 2015/9

Y1 - 2015/9

N2 - Pelvic inflammatory disease (PID) is a gynaecological inflammatory disorder with a high incidence that can lead to sequelae such as infertility, ectopic pregnancy and chronic pelvic pain. The International Union against Sexually Transmitted Infections (IUSTI) and the US Centers for Disease Control and Prevention (CDC) have issued treatment recommendations for the management of PID. The purpose of this review is to summarise the available evidence for the use of IUSTI- and CDC-recommended antibiotic therapies for PID. The main differences between recommendations concern alternative regimens for inpatient treatment and the use of oral moxifloxacin as an alternative outpatient regimen in the IUSTI guidelines. There is evidence supporting the use of the recommended antibiotic regimens, although with some variation in reported cure rates. This variation can be explained, in part, by the different diagnostic and evaluation criteria used in different trials. Adverse events that require discontinuation of antibiotic therapy are rarely observed. The main limitation of the current available evidence is the short-term follow-up, which does not allow full evaluation of the risks of long-term sequelae.

AB - Pelvic inflammatory disease (PID) is a gynaecological inflammatory disorder with a high incidence that can lead to sequelae such as infertility, ectopic pregnancy and chronic pelvic pain. The International Union against Sexually Transmitted Infections (IUSTI) and the US Centers for Disease Control and Prevention (CDC) have issued treatment recommendations for the management of PID. The purpose of this review is to summarise the available evidence for the use of IUSTI- and CDC-recommended antibiotic therapies for PID. The main differences between recommendations concern alternative regimens for inpatient treatment and the use of oral moxifloxacin as an alternative outpatient regimen in the IUSTI guidelines. There is evidence supporting the use of the recommended antibiotic regimens, although with some variation in reported cure rates. This variation can be explained, in part, by the different diagnostic and evaluation criteria used in different trials. Adverse events that require discontinuation of antibiotic therapy are rarely observed. The main limitation of the current available evidence is the short-term follow-up, which does not allow full evaluation of the risks of long-term sequelae.

KW - Antibiotic therapy

KW - CDC guidelines

KW - IUSTI guidelines

KW - Pelvic inflammatory disease

UR - http://www.scopus.com/inward/record.url?scp=84933059900&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2015.05.004

DO - 10.1016/j.ijantimicag.2015.05.004

M3 - Article

VL - 46

SP - 272

EP - 277

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 3

ER -